Cargando…

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Background: The approvals of immune checkpoint inhibitors for several cancer types and the rapidly growing recognition that T cell-based immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of cancer vaccines, including dendritic cell (DC)-based immunotherapy. Bloo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreira, Alvaro, Erdmann, Michael, Uslu, Ugur, Vass, Verona, Schuler, Gerold, Schuler-Thurner, Beatrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150785/ https://www.ncbi.nlm.nih.gov/pubmed/32121531 http://dx.doi.org/10.3390/pharmaceutics12030210

Ejemplares similares

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
por: Dörrie, Jan, et al.
Publicado: (2020)

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
por: Simon, Bianca, et al.
Publicado: (2018)

Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
por: Schuler-Thurner, Beatrice, et al.
Publicado: (2002)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
por: Koch, Elias A. T., et al.
Publicado: (2022)

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
por: Gerer, Kerstin F., et al.
Publicado: (2017)

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
por: Krückel, Annika, et al.
Publicado: (2019)

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019)

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
por: Kirchberger, Michael Constantin, et al.
Publicado: (2018)

Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
por: Schuler, G., et al.
Publicado: (1997)

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023)

Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis
por: Hu, Guoming, et al.
Publicado: (2020)

GM-CSF Monocyte-Derived Cells and Langerhans Cells As Part of the Dendritic Cell Family
por: Lutz, Manfred B., et al.
Publicado: (2017)

Repetitive Injections of Dendritic Cells Matured with Tumor Necrosis Factor α Induce Antigen-specific Protection of Mice from Autoimmunity
por: Menges, Mauritius, et al.
Publicado: (2002)

Dendritic Cell-Based Immunotherapy for Solid Tumors()()
por: Jung, Nam-Chul, et al.
Publicado: (2018)

Inflammatory Pseudo-tumor of the Liver Accompanied by Eosinophilia
por: Matsumoto, Yoshihide, et al.
Publicado: (2021)

Safety, feasibility and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial
por: Subbiah, Vivek, et al.
Publicado: (2015)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

The Modular Nature of Dendritic Cell Responses to Commensal and Pathogenic Fungi
por: Rizzetto, Lisa, et al.
Publicado: (2012)

Induction of Interleukin 10–Producing, Nonproliferating Cd4(+) T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells
por: Jonuleit, Helmut, et al.
Publicado: (2000)

The Role of T Lymphocytes in Cancer Patients Undergoing Immunotherapy with Autologous Dendritic Cells
por: Rodrigues, Cláudia M., et al.
Publicado: (2011)

DCVax®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress
por: Subbiah, Vivek, et al.
Publicado: (2013)

The Extracellular Domain of CD83 Inhibits Dendritic Cell–mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells
por: Lechmann, Matthias, et al.
Publicado: (2001)

Treatment of solid tumor with autologous natural killer cells in mouse models
por: Liao, Nan-Shih
Publicado: (2014)

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
por: Thurner, Beatrice, et al.
Publicado: (1999)

Tumor Rejection by Modulation of Tumor Stromal Fibroblasts
por: Schüler, Thomas, et al.
Publicado: (2003)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors
por: Poláková, Ingrid, et al.
Publicado: (2019)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors
por: Dolcetti, Riccardo, et al.
Publicado: (2020)

Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
por: Kim, Dae Suk, et al.
Publicado: (2011)

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
por: Fiammenghi, Laura, et al.
Publicado: (2010)

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors
por: Capuozzo, Maurizio, et al.
Publicado: (2023)

Editorial: Aldehyde dehydrogenase in clinical settings: Potential biomarker and therapeutic target in solid tumors
por: Aramini, Beatrice, et al.
Publicado: (2023)

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
por: Buschow, Sonja I., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fsqf8rvnu3rd327n78n3udu7c4